Jan Kehler, et al.

Appln No: Not Yet Assigned

Filed: Herewith - February 15, 2006

Page 29 of 30

INFORMATION DISCLOSURE STATEMENT

In order to ensure compliance with applicants' duty of disclosure under 37 C.F.R. §1.56 and §1.97(a)-(d), applicants request that the following references be considered and made of record in the above-identified application.

- PCT International Publication No. WO 97/10211, published 03/20/1997 (Sanofi Bichon);
- 2. European Application No. EP 0673928A, published 09/27/1995 (Sanofi);
- 3. US Patent No. 5,434,158, issued on 07/18/1995 (Shah Shrenik, et al.);
- 4. European Application No. EP 0068999A, published 01/05/1983 (Fabre SA Pierre);
- 5. Bonnaud, B. et al. (1987) "1-Aryl-2-(aminomethyl)cyclopropancarboxylic acid derivatives. A new series of potential antidepreassants", *Journal of Medicinal Chemistry*; 30(2): 318-325; and
- 6. PCT International Publication No. WO 03/051869, published 06/26/2003 (Bang Noergaard, et al.).

Pursuant to M.P.E.P. §609, applicants note that "Where the information listed (in an Information Disclosure Statement) is not in the English language, but was cited in a search report or other action by a foreign patent office in a counterpart foreign application, the requirement for a concise explanation of relevance can be satisfied by submitting an English-language version of the search report or action which indicates the degree of relevance found by the foreign office."

The above-listed references 1-6 were cited in the International Search Report issued November 4, 2004 in connection with PCT/DK2004/000538. A copy of the International Search Report is attached hereto.

C.F.R. §1.98(a)(2)(i) has been amended to eliminate the requirement in paragraph (a)(2)(i) for a copy of each U.S. patent or U.S. patent application publication listed in an IDS in a patent application regardless of the filing date of the application. Accordingly, a copy of reference 3 is not enclosed herewith. Copies of references 1, 2, 4, 5 and 6 are enclosed.

Jan Kehler, et al.

Appln No: Not Yet Assigned

Filed: Herewith - February 15, 2006

Page 30 of 30

It is respectfully requested that the Examiner consider the cited references and that copies of enclosed Form PTO/SB/08a and Form PTO/SB/08b be initialed and returned indicating that such information has been considered. Applicants respectfully request that the Examiner make the cited references of record in the subject application.

If a telephone interview would be of assistance in advancing prosecution of the above-identified application, applicants' undersigned attorney invites the Examiner to telephone the number provided below.

No fee, other than the enclosed \$5800.00 filing fee for the subject application, is deemed necessary in connection with filing this Preliminary Amendment and Information Disclosure Statement. However, if an additional fee is required, authorization is hereby given to charge this fee, and any other fees not covered by the enclosed check to Deposit Account Number 503201.

Respectfully submitted,

Stephen G. Kalinchak Registration No. 38,747

Lundbeck Research USA, Inc.

215 College Road

Paramus, New Jersey 07652

(201) 350-0781 (phone)

(201) 225-9571 (fax)

IAP20 Rec'd PCT/PTO 15 FEB 2006

PTO/SB/08a (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Sut	ostitute for form 1449A/PTO			Complete if Known 20 1 0 2			
				Application Number	Not yet Assigned		
IN	IFORMATION [DISCLOS	URE	Filing Date	Herewith - February 15, 2006		
STATEMENT BY APPLICANT				First Named Inventor	Jan Kehler		
				Art Unit	Not Yet Assigned		
	(Use as many sheets	as necessary)		Examiner Name	Not Yet Assigned		
Sheet	1	of	2	Attorney Docket Number	437-US-CIP		

Examiner	Cite No.1	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Initials*	No.'	Number-Kind Code ^{2 (f known)}	MM-DD-YYYY	Applicant of Cited Document		
		US- 5434158	07-18-1995	Shah Shrenik, et al.		
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
orridhe bijar bijardiliya biya daya daya daya daya		US-		The advisor of a file and a side appearing a process and a second and a planting above and a second and a sec		
		US-				
		US-				
***************************************		US-				
		US-	**************************************	Anger and the state of the stat		
		US-				
***************************************		US-	The state of the s			
		US-				
of the filter decorate management of the filter of the fil		US-	W 17 18 18 18 18 18 18 18 18 18 18 18 18 18			
		US-				
		US-				

	FOREIGN PATENT DOCUMENTS								
Examiner	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
Initials*		Country Code ³ 'Number ⁴ 'Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document		T ⁶			
*************	<u> </u>	WO 97/10211	03-20-1997	Sanofi		Т			
	<u> </u>	WO 03/051869	06-26-2003	H. Lundbeck A/S	***************************************				
		EP 0673928	09-27-1995	Sanofi	•				
		EP 0068999	01-05-1983	Fabre SA Pierre	•				
				••••••••••••••••••••••••	•••••••••••••••••••••••••••••••••••••••				

Examiner	 Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08b (07-05)

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for	form 1449B/PTO			Complete if Known P (A D S			
			1	Application Number	Not Yel Assigned 00 4 8 3		
INFO	RMATION DI	SCLO	SURE	Filing Date	Herewith - February 15, 2006		
STATEMENT BY APPLICANT				First Named Inventor	Michael Konkel		
			,	Art Unit	Not Yet Assigned		
	(Use as many sheets as	necessary)		Examiner Name	Not Yet Known		
Sheet	2	of	2	Attorney Docket Number	437-US-PCT		

		2 407-00-1-01					
NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
		Bonnaud, B. et al. (1987) "1-Aryl-2-(aminomethyl)cyclopropancarboxylic acid derivance new series of potential antidepreassants", Journal of Medicinal Chemistry; 30(2): 31	itives. A 18-325				
	····						
	······································	·					

***************************************	***************************************						

Examiner		Date					

$\overline{}$			·
	1	1	
	_		
Examiner	Date		
		1	
Signature	Considered		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.